Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-17

FDA Approved: SUMATRIPTAN — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

FDA approved a supplemental application for Sumatriptan succinate from Aurobindo Pharma Limited, resulting in updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sumatriptan (Sumatriptan)

Snippet

SUPPL AP for SUMATRIPTAN (SUMATRIPTAN SUCCINATE)